This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| FDA 510(k) | |
|---|---|
| Name | 510(k) |
| Agency | Food and Drug Administration |
| Statute | Food, Drug, and Cosmetic Act |
| Established | 1976 |
| Type | Premarket notification |
| Purpose | Demonstrate substantial equivalence for medical devices |
FDA 510(k) is a United States premarket notification pathway used to demonstrate that a proposed medical device is substantially equivalent to a legally marketed predicate device, enabling clearance to market without a full premarket approval application. The pathway interacts with statutes, regulations, and administrative practices arising from interactions among actors such as the United States Congress, the Supreme Court of the United States, and the Food and Drug Administration, and has been the subject of debate involving stakeholders including Johnson & Johnson, Medtronic, Stryker Corporation, Boston Scientific, and patient advocacy groups. The process shapes product introductions by manufacturers such as GE Healthcare, Siemens Healthineers, and Philips and touches clinical practice settings like Mayo Clinic, Johns Hopkins Hospital, and Cleveland Clinic.
The 510(k) pathway enables device manufacturers such as Abbott Laboratories and Becton, Dickinson and Company to seek marketing clearance by showing substantial equivalence to predicate devices cleared before the enactment of key rules, or to post-1976 predicates like those from Medtronic, Inc. and St. Jude Medical. The mechanism interacts with regulatory categories defined under the Food, Drug, and Cosmetic Act and implemented through regulations at the Code of Federal Regulations; devices range from low-risk products made by Baxter International to higher-risk devices historically cleared via 510(k) such as certain implants from Zimmer Biomet. The pathway contrasts with the De Novo (FDA) classification process and the higher evidentiary premarket approval (PMA) route used by firms including Intuitive Surgical.
The statutory authority for 510(k) processes originates in the Food, Drug, and Cosmetic Act as amended by congressional acts and informed by case law from courts including the United States Court of Appeals for the District of Columbia Circuit and decisions of the United States Supreme Court. Administrative authority rests with the Food and Drug Administration, whose center Center for Devices and Radiological Health implements device regulation, and whose rulemaking history involves notices and guidance documents interacting with agencies such as the Department of Health and Human Services and oversight by committees like the United States Senate Committee on Health, Education, Labor, and Pensions. Key legislative landmarks affecting device review include actions by the 94th United States Congress and later reforms debated in hearings featuring representatives from Pfizer, Eli Lilly and Company, and patient organizations such as the American Medical Association.
A complete 510(k) submission typically contains administrative information, device descriptions, proposed labeling, and performance data including bench testing, biocompatibility studies, and sometimes clinical data. Sponsors such as Boston Scientific Corporation must provide device specifications, risk analyses, and summaries of substantial equivalence comparing the subject device to predicate devices from companies like Cook Medical or models cleared for market by firms such as Smith & Nephew. Submissions rely on standards from bodies such as International Organization for Standardization and American Society for Testing and Materials, and may cite consensus documents from organizations like American Association of Medical Colleges in support of testing protocols.
FDA review of a 510(k) may result in clearance, a request for additional information, or a determination of non-substantial equivalence (NSE). Decision types include a 510(k) clearance letter, an NSE letter, and in limited situations, referral to a panel or transition to a premarket approval requirement. The timeline involves performance metrics tracked by the Government Accountability Office and oversight bodies such as the Office of Inspector General (United States Department of Health and Human Services), with interactions among FDA reviewers, external consultants, and industry representatives from corporations like Zimmer Holdings.
Special pathways and exemptions intersect with 510(k) when devices qualify for exemption from premarket notification or when novel devices pursue the De Novo (FDA) route. Exemptions may apply to certain Class I and Class II devices, impacting producers such as small innovators and startups spun out from institutions like Harvard University, Stanford University, and Massachusetts Institute of Technology. Emergency use authorizations issued during public health crises involve coordination with agencies including the Centers for Disease Control and Prevention and have parallels to expedited device pathways used by firms such as Moderna in medical countermeasure contexts.
Following clearance, manufacturers must meet postmarket requirements including adverse event reporting under the Medical Device Reporting regulations, Quality System Regulation obligations influenced by ISO 13485 standards, and recall actions coordinated with FDA recall authorities and entities such as Federal Emergency Management Agency in large-scale incidents. Enforcement actions have involved injunctions, warning letters, and consent decrees affecting companies like Theranos (noting separate factual contexts) and major manufacturers, with compliance activities involving legal counsel from firms like Covington & Burling and Hogan Lovells.
Criticism of the 510(k) pathway has come from academics, litigants, and policymakers including commentators at institutions such as Johns Hopkins Bloomberg School of Public Health, Harvard T.H. Chan School of Public Health, and watchdog reports from the Government Accountability Office. Litigation has involved plaintiffs represented by firms such as Skadden, Arps, Slate, Meagher & Flom and cited cases adjudicated in federal courts, prompting reforms including legislative proposals debated in the United States Senate and rulemaking initiatives from the Food and Drug Administration. Proposals for change address issues raised by high-profile recalls and safety events associated with devices from prominent manufacturers such as Johnson & Johnson, with stakeholders including professional societies like the American College of Cardiology advocating for modifications to evidence requirements, predicate selection, and transparency measures.
Category:United States medical regulation